Gastroparesis and Postprandial Distress Symptoms
Core Symptoms
- The American Gastroenterological Association notes that nausea and vomiting are typically the predominant and most persistent symptoms in medically refractory gastroparesis cases 1, 2
- Early satiety, defined as the inability to finish a normal-sized meal, is a key symptom of gastroparesis 1
- Postprandial fullness, a sensation of uncomfortable fullness that persists after eating, is a common symptom of gastroparesis 1
- Bloating, a subjective sensation of abdominal distension, is a symptom of gastroparesis 1, 2
- Abdominal pain, particularly epigastric discomfort or pain, is a symptom of gastroparesis 1, 2
- Weight loss and malnutrition can occur in more severe cases of gastroparesis 2
Pathophysiology and Clinical Distinctions
- The American College of Gastroenterology states that gastroparesis results from multiple pathophysiologic mechanisms, including impaired gastric accommodation, antral hypomotility, antroduodenal and pyloric dyscoordination, increased visceral perception, and vagal nerve injury 1, 2
- Functional dyspepsia is defined by bothersome epigastric pain, burning, postprandial fullness, or early satiation without structural disease, and is distinguished from gastroparesis by normal gastric emptying 1, 3
Symptom Assessment and Treatment
- The American Gastroenterological Association notes that symptoms correlate poorly with the degree of gastric emptying delay, and that exaggerated visceral perception, altered central processing, learned behaviors, and psychological distress can amplify symptom intensity independent of the actual degree of gastric emptying delay 1, 2
- Medication-induced symptoms, particularly from opioids and GLP-1 agonists, must be excluded as they can mimic gastroparesis 1, 2
- Hyperglycemia itself can slow gastric emptying in diabetic patients, so blood glucose control must be assessed 3, 4
- Clinicians should identify the predominant symptom and initiate treatment based on that specific symptom, such as antiemetic agents for nausea and vomiting, neuromodulators for abdominal pain, and dietary modifications for early satiety and postprandial fullness 1, 2, 3
Diagnostic Considerations for Gastroparesis with Gastric Electrical Stimulator
Gastroparesis-Related Symptom Progression
- The American Gastroenterological Association emphasizes that refractory gastroparesis progression typically manifests as severe, persistent nausea and vomiting, though abdominal pain can coexist, and medication-induced exacerbation from opioids or GLP-1 agonists must be excluded 5
- Diarrhea is not a typical gastroparesis symptom and suggests alternative or concurrent pathology, according to the American Gastroenterological Association 5, 6
Gastroparesis Mimics and Overlapping Conditions
- The American Gastroenterological Association guidelines highlight that cyclic vomiting syndrome presents with episodic severe nausea and vomiting but typically lacks the continuous diarrhea pattern 6
- Cannabinoid hyperemesis syndrome should be considered if there is cannabis use history, presenting with severe cyclic vomiting, as noted by the American Gastroenterological Association 6
- Narcotic bowel syndrome occurs with chronic opioid use and presents with paradoxical worsening of pain and gastrointestinal symptoms, according to the American Gastroenterological Association 6, 7
- Functional dyspepsia is distinguished by normal gastric emptying but shares symptom overlap including epigastric pain, bloating, and postprandial fullness, as stated by the American Gastroenterological Association 5
- Intestinal pseudo-obstruction can present with symptoms mimicking mechanical obstruction including pain, vomiting, and altered bowel habits, according to the American Gastroenterological Association 6
Diagnostic Approach
- Laboratory evaluation including complete blood count, metabolic panel, lipase, and lactate to assess for infection, inflammation, or ischemia is essential, as recommended by the American Gastroenterological Association 6
- Reviewing medication list for opioids, GLP-1 agonists, or other gastroparesis-exacerbating agents is crucial, according to the American Gastroenterological Association 5